{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T01:45:56Z","timestamp":1780364756030,"version":"3.54.1"},"reference-count":39,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>To investigate the expression of carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), CA19-9, CA724, and CA242 in serum and ascites of pseudomyxoma peritonei (PMP) patients and evaluate the predictive value of these\u00a0elevated biomarkers in pathological grade, completeness of cytoreduction (CC), and survival.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>From May 2009 to October 2019, a total of 512 patients diagnosed with PMP through pathology in Aerospace Center Hospital were enrolled. The serum and ascites tumor biomarkers were obtained. The diagnostic values between serum and ascites biomarkers in pathology and CC were compared by the receiver operating characteristic (ROC) curves. The correlation between pathology, cytoreduction, and biomarkers was calculated by univariate and multivariate logistic regression. The associations between different numbers of elevated biomarkers and survival status were examined using univariate and multivariate backward Cox proportional hazard regression models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results showed that the areas under the ROC curves (AUROC) in the diagnosis of CC were 0.798 (95% CI: 0.760\u20130.836) and 0.632 (95% CI: 0.588\u20130.676) in serum and ascites biomarkers, respectively. The elevated serum and ascites biomarkers were independent risk factors for both pathology and CC. The 1-year, 3-year, and 5-year survival rates were 89.07%, 73.22%, and 66.94%, respectively. Longer survival was observed in patients who had less than two elevated serum biomarkers compared with those with 2\u20133 and 4-5 elevated serum biomarkers (p &amp;lt; 0.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>CEA, CA125, CA19-9, CA724, and CA242 in serum and ascites can be used to judge the severity and predict the resectability. Furthermore, different numbers of elevated biomarkers can help determine the prognosis of PMP.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fonc.2021.594763","type":"journal-article","created":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T18:19:25Z","timestamp":1634667565000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["Prognostic Value of CEA, CA19-9, CA125, CA724, and CA242 in Serum and Ascites in Pseudomyxoma Peritonei"],"prefix":"10.3389","volume":"11","author":[{"given":"Lei","family":"Liang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyang","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuedi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xichao","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyan","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruiqing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/PAS.0000000000000535","article-title":"A Consensus for Classification and Pathologic Reporting of Pseudomyxoma Peritonei and Associated Appendiceal Neoplasia","volume":"40","author":"Carr","year":"2016","journal-title":"Am J Surg Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v12.i38.6124","article-title":"Management of Pseudomyxoma Peritonei","volume":"12","author":"Qu","year":"2006","journal-title":"World J Gastroenterol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1177\/030089160108700415","article-title":"Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy as a Curative Approach to Pseudomyxoma Peritonei Syndrome","volume":"87","author":"Sugarbaker","year":"2001","journal-title":"Tumori"},{"key":"B4","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S1055-3207(03)00026-7","article-title":"The Etiology, Clinical Presentation, and Management of Pseudomyxoma Peritonei","volume":"12","author":"Moran","year":"2003","journal-title":"Surg Oncol Clin N Am"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2010.03.005","article-title":"Cost Analysis of the Combined Procedure of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC)","volume":"36","author":"Baratti","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.03.021","article-title":"Tumour Markers in Colorectal Cancer: European Group on Tumour Markers (EGTM) Guidelines for Clinical Use","volume":"43","author":"Duffy","year":"2007","journal-title":"Eur J Cancer"},{"key":"B7","doi-asserted-by":"publisher","first-page":"494","DOI":"10.7150\/jca.21562","article-title":"Clinical Significance and Diagnostic Capacity of Serum TK1, CEA, CA 19-9 and CA 72-4 Levels in Gastric and Colorectal Cancer Patients","volume":"9","author":"Ning","year":"2018","journal-title":"J Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.ejogrb.2008.08.011","article-title":"Accuracy of CA 125 in the Diagnosis of Ovarian Tumors: A Quantitative Systematic Review","volume":"142","author":"Medeiros","year":"2009","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2017.09.009","article-title":"CA 19-9 to Peritoneal Carcinomatosis Index (PCI) Ratio Is Prognostic in Patients With Epithelial Appendiceal Mucinous Neoplasms and Peritoneal Dissemination Undergoing Cytoreduction Surgery and Intraperitoneal Chemotherapy:A Retrospective Cohort Study","volume":"43","author":"Kozman","year":"2017","journal-title":"Eur J Surg Oncol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/jso.23329","article-title":"Circulating Biomarkers: Predictors of Incomplete Cytoreduction and Powerful Determinants of Outcome in Pseudomyxoma Peritonei","volume":"108","author":"Kusamura","year":"2013","journal-title":"J Surg Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejso.2020.02.012","article-title":"Appendiceal Tumours and Pseudomyxoma Peritonei: Literature Review With PSOGI\/EURACAN Clinical Practice Guidelines for Diagnosis and Treatment","volume":"47","author":"Govaerts","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2010.05.024","article-title":"Clinical Utility of Elevated Biomarkers in Patients With Disseminated Appendiceal Malignancies Treated by Cytoreductive Surgery and HIPEC","volume":"36","author":"Ross","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.humpath.2016.02.022","article-title":"Expression of CEA, CA19-9, CA125, and EpCAM in Pseudomyxoma Peritonei","volume":"54","author":"Nummela","year":"2016","journal-title":"Hum Pathol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO Classification of Tumours of the Digestive System","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21054","article-title":"Consensus Statement on the Loco-Regional Treatment of Appendiceal Mucinous Neoplasms With Peritoneal Dissemination (Pseudomyxoma Peritonei)","volume":"98","author":"Moran","year":"2008","journal-title":"J Surg Oncol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20107","article-title":"Utility of CEA and CA 19-9 Biomarkers in Diagnosis and Prognostic Assessment of Mucinous Epithelial Cancers of the Appendix","volume":"87","author":"Carmignani","year":"2004","journal-title":"J Surg Oncol"},{"key":"B17","article-title":"Carbohydrate Antigen 19-9 (CA 19-9) Is an Independent Prognostic Indicator in Pseudomyxoma Peritonei Post Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy","volume":"4","author":"Koh","year":"2013","journal-title":"J Gastrointest Oncol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ejso.2019.02.030","article-title":"Peritoneal MRI in Patients Undergoing Cytoreductive Surgery and HIPEC: History, Clinical Applications, and Implementation","volume":"47","author":"Low","year":"2021","journal-title":"Eur J Surg Oncol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s13193-018-00870-w","article-title":"Analysis of Clinical Outcomes of Pseudomyxoma Peritonei From Appendicular Origin Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy-A Retrospective Study From INDEPSO","volume":"10","author":"Sinukumar","year":"2019","journal-title":"Indian J Surg Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1023\/B:GLYC.0000033631.35357.41","article-title":"Molecular Mechanism for Cancer-Associated Induction of Sialyl Lewis X and Sialyl Lewis A Expression\u2014The Warburg Effect Revisited","volume":"20","author":"Kannagi","year":"2004","journal-title":"Glycoconj J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2016.03.017","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in 1000 Patients With Perforated Appendiceal Epithelial Tumours","volume":"42","author":"Ansari","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.7166","article-title":"Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy","volume":"30","author":"Chua","year":"2012","journal-title":"J Clin Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-011-1303-8","article-title":"Early Recurrence of Pseudomyxoma Peritonei Following Treatment Failure of Cytoreductive Surgery and Perioperative Intraperitoneal Chemotherapy Is Indicative of a Poor Survival Outcome","volume":"27","author":"Chua","year":"2012","journal-title":"Int J Colorectal Dis"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10716","article-title":"Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei of Appendicular and Extra-Appendicular Origin","volume":"105","author":"Delhorme","year":"2018","journal-title":"Br J Surg"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/bjs5.50134","article-title":"Factors Influencing Long-Term Survival After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei Originating From Appendiceal Neoplasms","volume":"3","author":"van Eden","year":"2019","journal-title":"BJS Open"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1080\/02656736.2017.1310938","article-title":"Pseudomyxoma Peritonei: Natural History and Treatment","volume":"33","author":"Mittal","year":"2017","journal-title":"Int J Hyperthermia"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.7754\/Clin.Lab.2016.160921","article-title":"The Diagnostic Value of Carcinoembryonic Antigen and Squamous Cell Carcinoma Antigen in Lung Adenosquamous Carcinoma","author":"Jin","year":"2017","journal-title":"Clin Lab"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-150561","article-title":"The Association Between Preoperative Serum CEA Concentrations and Synchronous Liver Metastasis in Colorectal Cancer Patients","volume":"16","author":"Pakdel","year":"2016","journal-title":"Cancer Biomark"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197612)38:6<2310::AID-CNCR2820380618>3.0.CO;2-L","article-title":"Assessment of Serial Carcinoembryonic Antigen (CEA) Assays in Postoperative Detection of Recurrent Colorectal Cancer","volume":"38","author":"Sugarbaker","year":"1976","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 Binding Is a High Affifinity, Nglycan Dependent Interaction That Facilitates Peritoneal Metastasis of Ovarian Tumours","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol Cancer"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.00312","article-title":"The Cancer Antigen CA125 Represents a Novel Counter Receptor for Galectin- 1","volume":"116","author":"Seelenmeyer","year":"2003","journal-title":"J Cell Sci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1476-4598-9-11","article-title":"MUC16 Provides Immune Protection by Inhibiting Synapse Formation Between NK and Ovarian Tumour Cells","volume":"9","author":"Gubbels","year":"2010","journal-title":"Mol Cancer"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/15.6.1261","article-title":"CA125 Production by the Peritoneum: in-Vitro and in-Vivo Studies","volume":"15","author":"Epiney","year":"2000","journal-title":"Hum Reprod"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1007\/s10120-011-0091-8","article-title":"Clinical Significance of CA125 and CA72-4 in Gastric Cancer With Peritoneal Dissemination","volume":"15","author":"Emoto","year":"2012","journal-title":"Gastric Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-006-0189-2","article-title":"Peritoneal Lavage CEA\/CA125 Is a Prognostic Factor for Gastric Cancer Patients","volume":"133","author":"Yamamoto","year":"2007","journal-title":"J Cancer Res Clin Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/bs.pmbts.2018.12.007","article-title":"CA242 as a Biomarker for Pancreatic Cancer and Other Diseases","volume":"162","author":"Dou","year":"2019","journal-title":"Prog Mol Biol Transl Sci"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1002\/jso.21919","article-title":"The Relationships Between Perioperative CEA, CA 19-9, and CA72-4 and Recurrence in Gastric Cancer Patients After Curative Radical Gastrectomy","volume":"104","author":"Kim","year":"2011","journal-title":"J Surg Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.7863\/ultra.32.9.1565","article-title":"Role of Preoperative Sonography in the Diagnosis and Pathologic Staging of Pseudomyxoma Peritonei","volume":"32","author":"Li","year":"2013","journal-title":"J Ultrasound Med"},{"key":"B39","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s11605-019-04239-4","article-title":"Outcomes Following Cytoreduction and HIPEC for Pseudomyxoma Peritonei: 10-Year Experience","volume":"24","author":"Narasimhan","year":"2020","journal-title":"J Gastrointest Surg"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.594763\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,19]],"date-time":"2021-10-19T18:20:00Z","timestamp":1634667600000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.594763\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":39,"alternative-id":["10.3389\/fonc.2021.594763"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.594763","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,18]]},"article-number":"594763"}}